CXCR4 and cancer: Finally, despite successful pre-clinical studies, the addition of the anti-CXCR4 peptide LY2510924 to cancer therapy did not improve the efficacy of the treatments in phase II studies in lung cancer and renal cell carcinoma, respectively NCT01439568 [189] and NCT01391130 [190].